Top in ID: Hydroxychloroquine, remdesivir and COVID-19
Click Here to Manage Email Alerts
A recent study published in The Lancet further questions the safety and usefulness of hydroxychloroquine for the treatment of COVID-19, according to researchers. It was the top story in infectious disease last week.
Another top story was about the role of remdesivir (Gilead Science) in treating patients with COVID-19.
Read these and more top stories in infectious disease below:
Large study adds to questions about safety, usefulness of hydroxychloroquine for COVID-19
In late March, the FDA authorized emergency use of hydroxychloroquine for COVID-19. It later approved an abbreviated new drug application for the drug in response to a surge in demand. Read more.
Q&A: Remdesivir a ‘go-to’ COVID-19 treatment, but questions remain
Healio recently spoke with C. Buddy Creech, MD, MPH, associate professor of pediatrics and director of the Vanderbilt Vaccine Research Program at Vanderbilt University School of Medicine, about remdesivir’s place in treating patients with COVID-19. Read more.
Cancer increases cost of care for CDI by nearly $60,000
Patients with Clostridioides difficile infection who also have cancer spent more than 20 days longer in the hospital on average than those without Clostridioides difficile infection, according to a retrospective analysis in Infection Control and Hospital Epidemiology. This resulted in an average of nearly $60,000 more in the cost of care. Read more.
COVID-19 confers similar risk for severe disease in patients with, without HIV
Patients with COVID-19 who were also HIV-positive experienced a similar risk for severe disease, ICU admission and death due to COVID-19 compared with the general population, according to the results of a single-center study conducted in Italy. Read more.
Researchers scramble to meet ‘urgent need’ for COVID-19 vaccine
As deaths from COVID-19 increase to more than 100,000 in the United States, institutions around the world are working to develop an effective vaccine. Kaiser Permanente Washington Health Research Institute in Seattle is conducting a phase 1 clinical trial to assess an investigational vaccine, while Johnson & Johnson plans to initiate human clinical studies for its potential candidate by September. Read more.